Cargando…

The Acute Effects of Amyloid-Beta(1–42) on Glutamatergic Receptor and Transporter Expression in the Mouse Hippocampus

Alzheimer’s disease (AD) is the leading type of dementia worldwide. Despite an increasing burden of disease due to a rapidly aging population, there is still a lack of complete understanding of the precise pathological mechanisms which drive its progression. Glutamate is the main excitatory neurotra...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeung, Jason H. Y., Palpagama, Thulani H., Tate, Warren P., Peppercorn, Katie, Waldvogel, Henry J., Faull, Richard L. M., Kwakowsky, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978747/
https://www.ncbi.nlm.nih.gov/pubmed/32009891
http://dx.doi.org/10.3389/fnins.2019.01427
_version_ 1783490763748802560
author Yeung, Jason H. Y.
Palpagama, Thulani H.
Tate, Warren P.
Peppercorn, Katie
Waldvogel, Henry J.
Faull, Richard L. M.
Kwakowsky, Andrea
author_facet Yeung, Jason H. Y.
Palpagama, Thulani H.
Tate, Warren P.
Peppercorn, Katie
Waldvogel, Henry J.
Faull, Richard L. M.
Kwakowsky, Andrea
author_sort Yeung, Jason H. Y.
collection PubMed
description Alzheimer’s disease (AD) is the leading type of dementia worldwide. Despite an increasing burden of disease due to a rapidly aging population, there is still a lack of complete understanding of the precise pathological mechanisms which drive its progression. Glutamate is the main excitatory neurotransmitter in the brain and plays an essential role in the normal function and excitability of neuronal networks. While previous studies have shown alterations in the function of the glutamatergic system in AD, the underlying etiology of beta amyloid (Aβ(1–42)) induced changes has not been explored. Here we have investigated the acute effects of stereotaxic hippocampal Aβ(1–42) injection on specific glutamatergic receptors and transporters in the mouse hippocampus, using immunohistochemistry and confocal microscopy 3 days after Aβ(1–42) injection in aged male C57BL/6 mice, before the onset of neuronal cell death. We show that acute injection of Aβ(1–42) is sufficient to induce cognitive deficits 3 days post-injection. We also report no significant changes in glutamate receptor subunits GluA1, GluA2, VGluT1, and VGluT2 in response to acute injection of Aβ(1–42) when compared with the ACSF-vehicle injected mice. However, we observed increased expression in the DG hilus and ventral stratum (str.) granulosum, CA3 str. radiatum and str. oriens, and CA1 str. radiatum of the GluN1 subunit, and increased expression within the CA3 str. radiatum and decreased expression within the DG str. granulosum of the GluN2A subunit in Aβ(1–42) injected mice compared to NC, and a similar trend observed when compared to ACSF-injected mice. We also observed alterations in expression patterns of glutamatergic receptor subunits and transporters within specific layers of hippocampal subregions in response to a microinjection stimulus. These findings indicate that the pathological alterations in the glutamatergic system observed in AD are likely to be partially a result of both acute and chronic exposure to Aβ(1–42) and implies a much more complex circuit mechanism associated with glutamatergic dysfunction than simply glutamate-mediated excitotoxic neuronal death.
format Online
Article
Text
id pubmed-6978747
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-69787472020-02-01 The Acute Effects of Amyloid-Beta(1–42) on Glutamatergic Receptor and Transporter Expression in the Mouse Hippocampus Yeung, Jason H. Y. Palpagama, Thulani H. Tate, Warren P. Peppercorn, Katie Waldvogel, Henry J. Faull, Richard L. M. Kwakowsky, Andrea Front Neurosci Neuroscience Alzheimer’s disease (AD) is the leading type of dementia worldwide. Despite an increasing burden of disease due to a rapidly aging population, there is still a lack of complete understanding of the precise pathological mechanisms which drive its progression. Glutamate is the main excitatory neurotransmitter in the brain and plays an essential role in the normal function and excitability of neuronal networks. While previous studies have shown alterations in the function of the glutamatergic system in AD, the underlying etiology of beta amyloid (Aβ(1–42)) induced changes has not been explored. Here we have investigated the acute effects of stereotaxic hippocampal Aβ(1–42) injection on specific glutamatergic receptors and transporters in the mouse hippocampus, using immunohistochemistry and confocal microscopy 3 days after Aβ(1–42) injection in aged male C57BL/6 mice, before the onset of neuronal cell death. We show that acute injection of Aβ(1–42) is sufficient to induce cognitive deficits 3 days post-injection. We also report no significant changes in glutamate receptor subunits GluA1, GluA2, VGluT1, and VGluT2 in response to acute injection of Aβ(1–42) when compared with the ACSF-vehicle injected mice. However, we observed increased expression in the DG hilus and ventral stratum (str.) granulosum, CA3 str. radiatum and str. oriens, and CA1 str. radiatum of the GluN1 subunit, and increased expression within the CA3 str. radiatum and decreased expression within the DG str. granulosum of the GluN2A subunit in Aβ(1–42) injected mice compared to NC, and a similar trend observed when compared to ACSF-injected mice. We also observed alterations in expression patterns of glutamatergic receptor subunits and transporters within specific layers of hippocampal subregions in response to a microinjection stimulus. These findings indicate that the pathological alterations in the glutamatergic system observed in AD are likely to be partially a result of both acute and chronic exposure to Aβ(1–42) and implies a much more complex circuit mechanism associated with glutamatergic dysfunction than simply glutamate-mediated excitotoxic neuronal death. Frontiers Media S.A. 2020-01-17 /pmc/articles/PMC6978747/ /pubmed/32009891 http://dx.doi.org/10.3389/fnins.2019.01427 Text en Copyright © 2020 Yeung, Palpagama, Tate, Peppercorn, Waldvogel, Faull and Kwakowsky. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Yeung, Jason H. Y.
Palpagama, Thulani H.
Tate, Warren P.
Peppercorn, Katie
Waldvogel, Henry J.
Faull, Richard L. M.
Kwakowsky, Andrea
The Acute Effects of Amyloid-Beta(1–42) on Glutamatergic Receptor and Transporter Expression in the Mouse Hippocampus
title The Acute Effects of Amyloid-Beta(1–42) on Glutamatergic Receptor and Transporter Expression in the Mouse Hippocampus
title_full The Acute Effects of Amyloid-Beta(1–42) on Glutamatergic Receptor and Transporter Expression in the Mouse Hippocampus
title_fullStr The Acute Effects of Amyloid-Beta(1–42) on Glutamatergic Receptor and Transporter Expression in the Mouse Hippocampus
title_full_unstemmed The Acute Effects of Amyloid-Beta(1–42) on Glutamatergic Receptor and Transporter Expression in the Mouse Hippocampus
title_short The Acute Effects of Amyloid-Beta(1–42) on Glutamatergic Receptor and Transporter Expression in the Mouse Hippocampus
title_sort acute effects of amyloid-beta(1–42) on glutamatergic receptor and transporter expression in the mouse hippocampus
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978747/
https://www.ncbi.nlm.nih.gov/pubmed/32009891
http://dx.doi.org/10.3389/fnins.2019.01427
work_keys_str_mv AT yeungjasonhy theacuteeffectsofamyloidbeta142onglutamatergicreceptorandtransporterexpressioninthemousehippocampus
AT palpagamathulanih theacuteeffectsofamyloidbeta142onglutamatergicreceptorandtransporterexpressioninthemousehippocampus
AT tatewarrenp theacuteeffectsofamyloidbeta142onglutamatergicreceptorandtransporterexpressioninthemousehippocampus
AT peppercornkatie theacuteeffectsofamyloidbeta142onglutamatergicreceptorandtransporterexpressioninthemousehippocampus
AT waldvogelhenryj theacuteeffectsofamyloidbeta142onglutamatergicreceptorandtransporterexpressioninthemousehippocampus
AT faullrichardlm theacuteeffectsofamyloidbeta142onglutamatergicreceptorandtransporterexpressioninthemousehippocampus
AT kwakowskyandrea theacuteeffectsofamyloidbeta142onglutamatergicreceptorandtransporterexpressioninthemousehippocampus
AT yeungjasonhy acuteeffectsofamyloidbeta142onglutamatergicreceptorandtransporterexpressioninthemousehippocampus
AT palpagamathulanih acuteeffectsofamyloidbeta142onglutamatergicreceptorandtransporterexpressioninthemousehippocampus
AT tatewarrenp acuteeffectsofamyloidbeta142onglutamatergicreceptorandtransporterexpressioninthemousehippocampus
AT peppercornkatie acuteeffectsofamyloidbeta142onglutamatergicreceptorandtransporterexpressioninthemousehippocampus
AT waldvogelhenryj acuteeffectsofamyloidbeta142onglutamatergicreceptorandtransporterexpressioninthemousehippocampus
AT faullrichardlm acuteeffectsofamyloidbeta142onglutamatergicreceptorandtransporterexpressioninthemousehippocampus
AT kwakowskyandrea acuteeffectsofamyloidbeta142onglutamatergicreceptorandtransporterexpressioninthemousehippocampus